Dr. Marc Pfeffer, MD

• Cardiology

• Advanced Heart Failure & Transplant Cardiology

• Internal Medicine

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Brigham And Womens Hospital

  Fellowship Hospital, 1980

• Brigham And Womens Hospital

  Residency Hospital, 1979

• Brigham And Womens Hospital

  Internship Hospital, 1977

• University Of Oklahoma College Of Medicine

  Medical School, 1976

• Enhancing Trial Integrity by Protecting the Independence of Data Monitoring Committees in Clinical Trials, 2014-08-08

• Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction, 2020-12-10

• Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial, 2020-10-12

• Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure with Preserved Ejection Fraction: The TOPCAT Trial, 2019-01-21

• Heart Failure with Preserved Ejection Fraction: In Perspective, 2019-05-24

• Increased Risk of Stroke with Darbepoetin Alfa in Anaemic Heart Failure Patients with Diabetes and Chronic Kidney Disease, 2015-10-01

• Physical Activity and Prognosis in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial, 2017-06-21

• B-type natriuretic peptide and cardiac troponin I are associated with adverse outcomes in stable kidney transplant recipients, 2015-12-07

• Data monitoring committees: Promoting best practices to address emerging challenges, 2017-02-01

• Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease, 2014-04-09

• SARS-CoV-2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices, 2020-09-28

• Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF, 2021-10-05

• The Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure with Preserved Ejection Fraction and the Impact of Spironolactone, 2015-10-16

• C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT), 2016-09-16

• Treatment of Anemia with Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes - Analyses from the Trial to Reduce cardiovascular Events with Aranesp Therapy (TREAT), 2018-12-19

• Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial, 2018-07-20

• Alternatives to hazard ratios for comparing efficacy or safety of therapies in noninferiority studies, 2015-07-21

• Genetic profiling of fatty acid desaturase polymorphisms identifies patients who may benefit from high-dose omega-3 fatty acids in cardiac remodeling after acute myocardial infarction-Post-hoc analysis from the OMEGA-REMODEL randomized controlled trial, 2019-09-18

• Impact of Sacubitril/Valsartan compared to Ramipril on cardiac structure and function following acute myocardial infarction: The PARADISE-MI Echocardiographic Sub-Study, 2022-09-09

• Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes, 2022-06-30

• Influence of Prior Heart Failure Hospitalization on Cardiovascular Events in Patients with Reduced and Preserved Ejection Fraction, 2014-05-29

• Association of Hyper-polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction, 2021-10-22

• ASSESSMENT OF MYOCARDIAL VIABILITY AND LEFT VENTRICULAR FUNCTION IN PATIENTS SUPPORTED BY A LEFT VENTRICULAR ASSIST DEVICE, 2014-01-27

• Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure with Preserved Ejection Fraction: TOPCAT, 2019-06-21

• Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (From the TOPCAT Study), 2018-11-24

• Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring and analyzing a comparative clinical study, 2012-08-22

• Impact of sacubitril/valsartan versus ramipril on total heart failure events in the PARADISE-MI Trial, 2021-11-19

• Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration, 2018-12-16

• Exercise Training as Therapy for Heart Failure: Current Status and Future Directions, 2016-03-12

• Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction, 2017-10-25

• Red blood cell distribution width and mortality risk in a community-based prospective cohort: NHANES III RDW and mortality risk, 2009-03-23

• Baseline Characteristics of Participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial, 2008-11-20

• On the Restricted Mean Survival Time Curve in Survival Analysis, 2015-08-24

• Functionally-Competent Cardiac Stem Cells Can Be Isolated from Endomyocardial Biopsies of Patients with Advanced Cardiomyopathies, 2011-02-17

• The Prognostic Importance of Impaired Systolic Function in Heart Failure with Preserved Ejection Fraction and the Impact of Spironolactone, 2015-06-30

• Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation, 2017-04-27

• Renal function estimation and Cockcroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart ‘OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives, 2016-11-10

• Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes, 2017-09-25

• Rejoinder, 2017-01-31

• Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference, 2017-08-01

• Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT), 2015-04-29

• Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study P. Welsh et al., 2017-09-27

• Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients: Primary Results from the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial, 2011-04-11

• Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the TREAT trial, 2017-12-14

• Prognostic Importance of Left Ventricular Mechanical Dyssynchrony in Heart Failure With Preserved Ejection Fraction, 2017-03-21

• Developing Therapies for Heart Failure with Preserved Ejection Fraction: Current State and Future Directions, 2014-05-02

• Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: Recurrent hospitalizations and mortality, 2017-09-04

• Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials, 2022-06-18

• Predictors of Heart Failure in Patients with Stable Coronary Artery Disease: A PEACE Study, 2009-04-14

• Angiotensin-Neprilysin Inhibition and Renal Outcomes Across the Spectrum of Ejection Fraction in Heart Failure, 2022-01-18

• Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients with Stable Coronary Disease, 2011-12-16

• Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials, 2016-11-13